|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Campbell SL, Khosravi-Far R, Rossman KL,
Clark GJ and Der CJ: Increasing complexity of Ras signaling.
Oncogene. 17:1395–1413. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bos JL, Fearon ER, Hamilton SR, Verlaan-de
Vries M, van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of
ras gene mutations in human colorectal cancers. Nature.
327:293–297. 1987. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Finkelstein SD, Sayegh R, Christensen S
and Swalsky PA: Genotypic classification of colorectal
adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation
type. Cancer. 71:3827–3838. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bourne HR, Sanders DA and McCormick F: The
GTPase superfamily: Conserved structure and molecular mechanism.
Nature. 349:117–127. 1991. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khosravi-Far R, Solski PA, Clark GJ, Kinch
MS and Der CJ: Activation of Rac1, RhoA, and mitogen-activated
protein kinases is required for Ras transformation. Mol Cell Biol.
15:6443–6453. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moorman JP, Bobak DA and Hahn CS:
Inactivation of the small GTP binding protein Rho induces
multinucleate cell formation and apoptosis in murine T lymphoma
EL4. J Immunol. 156:4146–4153. 1996.PubMed/NCBI
|
|
8
|
Perona R, Esteve P, Jiménez B, Ballestero
RP, Ramón y Cajal S and Lacal JC: Tumorigenic activity of rho genes
from Aplysia californica. Oncogene. 8:1285–1292. 1993.PubMed/NCBI
|
|
9
|
Prendergast GC, Khosravi-Far R, Solski PA,
Kurzawa H, Lebowitz PF and Der CJ: Critical role of Rho in cell
transformation by oncogenic Ras. Oncogene. 10:2289–2296.
1995.PubMed/NCBI
|
|
10
|
Etienne-Manneville S and Hall A: Rho
GTPases in cell biology. Nature. 420:629–635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sahai E and Marshall CJ: RHO-GTPases and
cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar
|
|
12
|
Wherlock M and Mellor H: The Rho GTPase
family: A Racs to Wrchs story. J Cell Sci. 115:239–240.
2002.PubMed/NCBI
|
|
13
|
Yoshioka K, Nakamori S and Itoh K:
Overexpression of small GTP-binding protein RhoA promotes invasion
of tumor cells. Cancer Res. 59:2004–2010. 1999.PubMed/NCBI
|
|
14
|
Paterson HF, Self AJ, Garrett MD, Just I,
Aktories K and Hall A: Microinjection of recombinant p21rho induces
rapid changes in cell morphology. J Cell Biol. 111:1001–1007. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramakers GJ and Moolenaar WH: Regulation
of astrocyte morphology by RhoA and lysophosphatidic acid. Exp Cell
Res. 245:252–262. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soga N, Namba N, McAllister S, Cornelius
L, Teitelbaum SL, Dowdy SF, Kawamura J and Hruska KA: Rho family
GTPases regulate VEGF-stimulated endothelial cell motility. Exp
Cell Res. 269:73–87. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sahai E, Olson MF and Marshall CJ:
Cross-talk between Ras and Rho signalling pathways in
transformation favours proliferation and increased motility. EMBO
J. 20:755–766. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Senger DL, Tudan C, Guiot MC, Mazzoni IE,
Molenkamp G, LeBlanc R, Antel J, Olivier A, Snipes GJ and Kaplan
DR: Suppression of Rac activity induces apoptosis of human glioma
cells but not normal human astrocytes. Cancer Res. 62:2131–2140.
2002.PubMed/NCBI
|
|
19
|
Embade N, Valerón PF, Aznar S,
López-Collazo E and Lacal JC: Apoptosis induced by Rac GTPase
correlates with induction of FasL and ceramides production. Mol
Biol Cell. 11:4347–4358. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abraham MT, Kuriakose MA, Sacks PG, Yee H,
Chiriboga L, Bearer EL and Delacure MD: Motility-related proteins
as markers for head and neck squamous cell cancer. Laryngoscope.
111:1285–1289. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fritz G, Just I and Kaina B: Rho GTPases
are over-expressed in human tumors. Int J Cancer. 81:682–687. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Horiuchi A, Imai T, Wang C, Ohira S, Feng
Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA
and RhoC, is associated with tumor progression in ovarian
carcinoma. Lab Invest. 83:861–870. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kamai T, Arai K, Tsujii T, Honda M and
Yoshida K: Overexpression of RhoA mRNA is associated with advanced
stage in testicular germ cell tumour. BJU Int. 87:227–231. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kamai T, Kawakami S, Koga F, Arai G,
Takagi K, Arai K, Tsujii T and Yoshida KI: RhoA is associated with
invasion and lymph node metastasis in upper urinary tract cancer.
BJU Int. 91:234–238. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jaffe AB and Hall A: Rho GTPases:
Biochemistry and biology. Annu Rev Cell Dev Biol. 21:247–269. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ellenbroek SI and Collard JG: Rho GTPases:
Functions and association with cancer. Clin Exp Metastasis.
24:657–672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vega FM and Ridley AJ: Rho GTPases in
cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Olivier M, Eeles R, Hollstein M, Khan MA,
Harris CC and Hainaut P: The IARC TP53 database: New online
mutation analysis and recommendations to users. Hum Mutat.
19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang S, Bucana CD, Van Arsdall M and
Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity
and metastasis of tumor cells. Oncogene. 21:2504–2512. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schindler C, Levy DE and Decker T:
JAK-STAT signaling: From interferons to cytokines. J Biol Chem.
282:20059–20063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stark GR and Darnell JE Jr: The JAK-STAT
pathway at twenty. Immunity. 36:503–514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McKenna SL, McGowan AJ and Cotter TG:
Molecular mechanisms of programmed cell death. Adv Biochem Eng
Biotechnol. 62:1–31. 1998.PubMed/NCBI
|
|
33
|
Leist M and Jäättelä M: Four deaths and a
funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell
Biol. 2:589–598. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carson JP, Kulik G and Weber MJ:
Antiapoptotic signaling in LNCaP prostate cancer cells: A survival
signaling pathway independent of phosphatidylinositol 3′-kinase and
Akt/protein kinase B. Cancer Res. 59:1449–1453. 1999.PubMed/NCBI
|
|
35
|
Lin J, Adam RM, Santiestevan E and Freeman
MR: The phosphatidylinositol 3′-kinase pathway is a dominant growth
factor-activated cell survival pathway in LNCaP human prostate
carcinoma cells. Cancer Res. 59:2891–2897. 1999.PubMed/NCBI
|
|
36
|
Beale PJ, Rogers P, Boxall F, Sharp SY and
Kelland LR: BCL-2 family protein expression and platinum drug
resistance in ovarian carcinoma. Br J Cancer. 82:436–440.
2000.PubMed/NCBI
|
|
37
|
Moorehead RA and Singh G: Influence of the
proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol.
59:337–345. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shimizu S, Narita M and Tsujimoto Y: Bcl-2
family proteins regulate the release of apoptogenic cytochrome c by
the mitochondrial channel VDAC. Nature. 399:483–487. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kagawa S, Pearson SA, Ji L, Xu K,
McDonnell TJ, Swisher SG, Roth JA and Fang B: A binary adenoviral
vector system for expressing high levels of the proapoptotic gene
bax. Gene Ther. 7:75–79. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rossé T, Olivier R, Monney L, Rager M,
Conus S, Fellay I, Jansen B and Borner C: Bcl-2 prolongs cell
survival after Bax-induced release of cytochrome c. Nature.
391:496–499. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Finucane DM, Bossy-Wetzel E, Waterhouse
NJ, Cotter TG and Green DR: Bax-induced caspase activation and
apoptosis via cytochrome c release from mitochondria is inhibitable
by Bcl-xL. J Biol Chem. 274:2225–2233. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kitanaka C, Namiki T, Noguchi K, Mochizuki
T, Kagaya S, Chi S, Hayashi A, Asai A, Tsujimoto Y and Kuchino Y:
Caspase-dependent apoptosis of COS-7 cells induced by Bax
overexpression: Differential effects of Bcl-2 and Bcl-xL on
Bax-induced caspase activation and apoptosis. Oncogene.
15:1763–1772. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiang J, Chao DT and Korsmeyer SJ:
BAX-induced cell death may not require interleukin 1
beta-converting enzyme-like proteases. Proc Natl Acad Sci USA.
93:14559–14563. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kagawa S, Gu J, Honda T, McDonnell TJ,
Swisher SG, Roth JA and Fang B: Deficiency of caspase-3 in MCF7
cells blocks Bax-mediated nuclear fragmentation but not cell death.
Clin Cancer Res. 7:1474–1480. 2001.PubMed/NCBI
|
|
45
|
Sethi G, Ahn KS and Aggarwal BB: Targeting
nuclear factor-kappa B activation pathway by thymoquinone: Role in
suppression of antiapoptotic gene products and enhancement of
apoptosis. Mol Cancer Res. 6:1059–1070. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bellarosa D, Ciucci A, Bullo A, Nardelli
F, Manzini S, Maggi CA and Goso C: Apoptotic events in a human
ovarian cancer cell line exposed to anthracyclines. J Pharmacol Exp
Ther. 296:276–283. 2001.PubMed/NCBI
|
|
47
|
Keane MM, Ettenberg SA, Nau MM, Russell EK
and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in
breast cell lines. Cancer Res. 59:734–741. 1999.PubMed/NCBI
|
|
48
|
Kottke TJ, Blajeski AL, Martins LM, Mesner
PW Jr, Davidson NE, Earnshaw WC, Armstrong DK and Kaufmann SH:
Comparison of paclitaxel-, 5-fluoro-2′-deoxyuridine-, and epidermal
growth factor (EGF)-induced apoptosis. Evidence for EGF-induced
anoikis. J Biol Chem. 274:15927–15936. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Staudt LM: Oncogenic activation of
NF-kappaB. Cold Spring Harb Perspect Biol. 2:a0001092010.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
DiDonato JA, Mercurio F and Karin M: NF-κB
and the link between inflammation and cancer. Immunol Rev.
246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Calaf GM and Hei TK: Establishment of a
radiation- and estrogen-induced breast cancer model.
Carcinogenesis. 21:769–776. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Koh MS and Moon A: Activation of H-Ras and
Rac1 correlates with epidermal growth factor-induced invasion in
Hs578T and MDA-MB-231 breast carcinoma cells. Biochem Biophys Res
Commun. 406:25–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Parri M and Chiarugi P: Rac and Rho
GTPases in cancer cell motility control. Cell Commun Signal.
8:232010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang B, Zhang Y and Shacter E: Caspase
3-mediated inactivation of rac GTPases promotes drug-induced
apoptosis in human lymphoma cells. Mol Cell Biol. 23:5716–5725.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Osaki M, Tatebe S, Goto A, Hayashi H,
Oshimura M and Ito H: 5-Fluorouracil (5-FU) induced apoptosis in
gastric cancer cell lines: Role of the p53 gene. Apoptosis.
2:221–226. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Violette S, Poulain L, Dussaulx E, Pepin
D, Faussat AM, Chambaz J, Lacorte JM, Staedel C and Lesuffleur T:
Resistance of colon cancer cells to long-term 5-fluorouracil
exposure is correlated to the relative level of Bcl-2 and Bcl-X(L)
in addition to Bax and p53 status. Int J Cancer. 98:498–504. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lu Y, Zhang Z, Yan Z, Chen L, Deng W,
Lotze M, Wang Z, Lin X and Li LY: Recombinant GnRH-p53 protein
sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis
in vitro and in vivo. Apoptosis. 18:1214–1223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shen Y, Devgan G, Darnell JE Jr and
Bromberg JF: Constitutively activated Stat3 protects fibroblasts
from serum withdrawal and UV-induced apoptosis and antagonizes the
proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA.
98:1543–1548. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Uetsuka H, Haisa M, Kimura M, Gunduz M,
Kaneda Y, Ohkawa T, Takaoka M, Murata T, Nobuhisa T, Yamatsuji T,
et al: Inhibition of inducible NF-kappaB activity reduces
chemoresistance to 5-fluorouracil in human stomach cancer cell
line. Exp Cell Res. 289:27–35. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kodach LL, Bos CL, Durán N, Peppelenbosch
MP, Ferreira CV and Hardwick JC: Violacein synergistically
increases 5-fluorouracil cytotoxicity, induces apoptosis and
inhibits Akt-mediated signal transduction in human colorectal
cancer cells. Carcinogenesis. 27:508–516. 2006. View Article : Google Scholar
|
|
62
|
Wang W, McLeod HL and Cassidy J:
Disulfiram-mediated inhibition of NF-kappaB activity enhances
cytotoxicity of 5-fluorouracil in human colorectal cancer cell
lines. Int J Cancer. 104:504–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wu H, Li W, Wang T, Shu Y and Liu P:
Paeoniflorin suppress NF-kappaB activation through modulation of I
kappaB alpha and enhances 5-fluorouracil-induced apoptosis in human
gastric carcinoma cells. Biomed Pharmacother. 62:659–666. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Vinod BS, Antony J, Nair HH,
Puliyappadamba VT, Saikia M, Narayanan SS, Bevin A and Anto RJ:
Mechanistic evaluation of the signaling events regulating
curcumin-mediated chemosensitization of breast cancer cells to
5-fluorouracil. Cell Death Dis. 4:e5052013. View Article : Google Scholar : PubMed/NCBI
|
